Remove Drug Pricing Remove Pharmaceutical Manufacturing Remove Webinar
article thumbnail

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. Click here to see the original post from May 2022.

article thumbnail

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. But for now, the 2022 data provide fresh inconvenient facts for the drug pricing flat earthers (#DPFE).

article thumbnail

Gross-to-Net Bubble Update: Net Prices Drop (Again) at Six Top Drugmakers (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Update: 340B Controversies and Outlook. Time for Drug Channels ' annual update on pricing at six of the largest pharmaceutical manufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi.